Tumor necrosis factor receptor
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load=' | + | <StructureSection load='1ext' size='340' side='right' caption='Structure of human TNFRSF-18 extracellular domain (PDB code [[2q1m]]).' scene=''> |
== Function == | == Function == | ||
| - | '''Tumor necrosis factor receptor''' (TNFR) or '''death receptor''' is a trimeric cytokine receptor which binds TNF<ref>PMID:10358762</ref>. TNFR family contains several members and superfamily (TNFRSF) members. | + | '''Tumor necrosis factor receptor''' (TNFR) or '''death receptor''' is a trimeric cytokine receptor which binds TNF<ref>PMID:10358762</ref>. TNFR family contains several members and superfamily (TNFRSF) members. <br /> |
* '''TNFRSF 1''' is called '''Lymphotoxin-α or TNF-β''';<br /> | * '''TNFRSF 1''' is called '''Lymphotoxin-α or TNF-β''';<br /> | ||
* '''TNFRSF 3''' is called '''TNFR-III''';<br /> | * '''TNFRSF 3''' is called '''TNFR-III''';<br /> | ||
| Line 23: | Line 23: | ||
* '''TNFRSF 18''' is called '''GITRL''';<br /> | * '''TNFRSF 18''' is called '''GITRL''';<br /> | ||
* '''TNFRSF 21''' is called '''Dr6''';<br /> | * '''TNFRSF 21''' is called '''Dr6''';<br /> | ||
| - | |||
| - | |||
| - | == Disease == | ||
== Relevance == | == Relevance == | ||
| + | TRAPS - a condition characterized by recurrent episodes of fever is associated with TNFR<ref>PMID:24609716</ref>. | ||
== Structural highlights == | == Structural highlights == | ||
| + | The extracellular domain of TNFR contains 2 to 6 cysteine-rich domains (CRD). The CRD domains are ca. 40 amino-acid long and contain 4-6 cysteine residues. The CRD are involved in binding of TNF. | ||
</StructureSection> | </StructureSection> | ||
Revision as of 09:23, 28 September 2016
| |||||||||||
3D structures of tumor necrosis factor receptor
Updated on 28-September-2016
References
- ↑ Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-67. PMID:10358762 doi:http://dx.doi.org/10.1146/annurev.immunol.17.1.331
- ↑ Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015 Apr;34(4):807-9. doi: 10.1007/s10067-014-2556-8. Epub 2014, Mar 11. PMID:24609716 doi:http://dx.doi.org/10.1007/s10067-014-2556-8

